TY  - CHAP
M1  - Book, Section
TI  - Chapter 61. Perioperative Management of Patients Who Are Receiving Oral Anticoagulant Therapy
A1  - Donadini, Marco Paolo
A1  - Douketis, James D.
A2  - McKean, Sylvia C.
A2  - Ross, John J.
A2  - Dressler, Daniel D.
A2  - Brotman, Daniel J.
A2  - Ginsberg, Jeffrey S.
Y1  - 2012
N1  - 
T2  - Principles and Practice of Hospital Medicine
AB  - The  perioperative  management  of  patients  who  require  interruption  of  a  vitamin  K  antagonist  (VKA)  because  of  surgery  or  another  non-invasive  procedure  is  a  common  and  sometimes  challenging  clinical  problem.  Bridging  anticoagulation  refers  to  the  use  of  a  short-acting  anticoagulant,which  is  usually  therapeutic-dose  subcutaneous  low-molecular-weight  heparin  (LMWH)  such  as  enoxaparin  1  mg/kg  twice-daily,  administered  during  the  time  when  a  VKA  is  interrupted  and  there  is  no  therapeutic  anticoagulation.  However,  there  is  no  standardized  definition  of  ’bridging  anticoagulation’  and  other  treatment  regimens,  including  low-dose  (enoxaparin  40  mg  once-daily)  or  intermediate-dose  (eg,  enoxaparin  40  mg  twice-daily)  LMWH  regimens,  have  been  used,  particularly  in  selected  patients  at  high  risk  for  bleeding  complications.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=56195401
ER  -